News

Daniel Basting, Senior Scientist at Bayer AG, has taken over the role of project lead of the European Lead Factory (ELF). Daniel replaces Volkhart Min-Jian Li, Associate Director Early Stage Alliance Management at Bayer AG after 2.5 years of valuable service to the consortium.

A team of partners from the European Lead Factory (ELF) and FAIRplus (a fellow Innovative Medicines Initiative-funded project) joined forces recently in another example of

The European Lead Factory (ELF) is a pan-European drug discovery project and flagship open innovation resource.

With the world still in the grasp of continued Covid-19 infections and the emergence of new variants, we are proud to announce an exciting new development for one of our SARS-CoV2 programmes.

On 4 November 2022, after two years of online discussions, members of the European Lead Factory (ELF) met in person for the Annual Consortium Meeting. The event was hosted by ELF partner Grünenthal at their headquarters in Aachen, Germany.

We’re pleased to announce the completion of one of the SARS-CoV-2 programmes, selected for screening in 2020. The programme is now open for partnering opportunities.

The European Lead Factory (ELF) has helped identify two drug candidates for cancer treatment that have now progressed to phase 1 clinical trial testing.

In an exciting new development, the European Lead Factory (ELF) is now, for the first time, offering its services and assets to charities and foundations around the world.

In a recent Comment in Nature Reviews Drug Discovery, members of the ELF illustrate the unique ELF concept, share progress and provide an insight into future directions.

New research, based on the results and improved hit compounds delivered by the European Lead Factory (ELF), has led to the discovery of a new class of drug that has the potential to reverse antibiotic resistance for conditions such as pneumonia and sepsis.

Are you working on a High Content Screening (HCS) assay, and would you like to screen it at the ELF? Then we encourage you to submit your screening proposal soon, as we have opened our final call for High Content Screening.

As part of a series of interviews that put members of the European Lead Factory (ELF) in the spotlight, we recently had the chance to speak with all three members of the ELF Programme Clearance Team (PCT): Phil Jones of BioAscent, Steven van Helden and Freek Janssen of Pivot Park Screening Centre (PPSC).

On Tuesday 30 November, members of the European Lead Factory (ELF) will participate in a webinar organised by the Young Scientists Network (YSN) of the European Federation of Medicinal Chemistry and Chemical Biology (EFMC).

On 28 June 2021, the European Lead Factory (ELF) hosted a webinar organised in collaboration with Société de Chimie Thérapeutique (SCT).

In 2019, the European Lead Factory (ELF) established its current compound library, the ESCulab Compound Collection (ECC).